Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly's obesity pill helped patients maintain weight loss after they switched from injectable drugs, outcomes that could ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...